Prognostic prediction of clear cell renal cell carcinoma based on lipid metabolism-related lncRNA risk coefficient model

Abstract

Objective: In order to predict the prognosis in patients with clear cell renal cell carcinoma (ccRCC) so as to understand cancer lipid metabolism and sensitivity to immune-targeting drugs, model algorithms were used to establish a risk coefficient model of long non-coding RNAs (lncRNAs) associated with lipid metabolism.Methods: The transcriptome data were retrieved from TCGA, and lncRNAs associated with lipid metabolism were obtained through Pearson correlation and differential expression analyses. Differentially expressed lipid metabolism-related lncRNAs and lipid metabolism-related lncRNA pairs were obtained using the R language software. The minimum absolute shrinkage method and the selector operation regression method were used to construct the model and draw the receiver operator characteristic curve. High-risk patients were differentiated from low-risk patients through the cut-off value, and the correlation analyses of the high-risk subgroup and low-risk subgroup were performed.Results: This research discovered that 25 pairs of lncRNAs were associated with the lipid metabolism of ccRCC, and 12 of these pairs were utilized to build the model. In combination with clinical data, the areas under the 1-, 3- and 5-year survival curves of ccRCC patients were 0.809, 0.764 and 0.792, separately. The cut-off value was used to perform subgroup analysis. The results showed that high-risk patients had poor prognosis. The results of Cox multivariate regressive analyses revealed that age and risk score were independent prediction factors of ccRCC prognosis. In addition, immune cell infiltration, the levels of gene expression at immune checkpoints, and high-risk patients more susceptible to sunitinib-targeted treatment were assessed by the risk model.Conclusion: Our team identified new prognostic markers of ccRCC and established risk models that could assess the prognosis of ccRCC patients and help determine which type of patients were more susceptible to sunitinib. These discoveries are vital for the optimization of risk stratification and personalized management.

Unravelling the complexity of kidney renal clear cell carcinoma prognosis: integrating chromatin regulators, gene signatures and associated immune landscapes

“…The current therapeutic arsenal for kidney renal clear cell carcinoma encompasses surgical resection, radiotherapy, and chemotherapy. Unfortunately, this malignancy exhibits robust resistance to these modalities, with recurrence and metastasis persisting even after the radical resection of the primary mass [28][29][30]. The limited e cacy of these interventions necessitates the exploration of alternative avenues, leading molecularly targeted therapies to emerge as a prominent choice for advanced kidney renal clear cell carcinoma [31].…”

Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies

“…It has the worst prognosis among all the most frequent RCC variants [ 31 , 32 ]. About 20–30% of patients have metastasis, and 30% of those with a localized carcinoma at an advanced stage will develop metastases [ 33 ]. The metastatic form is more aggressive, and it is related with a large mortality rate [ 34 , 35 ].…”

Paraoxonase‐2 shRNA‐mediated gene silencing suppresses proliferation and migration, while promotes chemosensitivity in clear cell renal cell carcinoma cell lines

“…2 The metastatic form is the most aggressive and is associated with a high mortality rate: approximately 20%-30% of patients have metastases and about 30% of those with an advanced stage ccRCC will develop metastases, mainly in lungs, liver, and bones and, for about 15%, in lymph nodes. 3,4 Among genitourinary cancers, ccRCC displays the highest mortality rate and clinical outcomes are still unsatisfactory mainly due to drug resistance which, coupled with a late diagnosis and a tendency to metastasize, leads to a very low survival. Indeed, after treatment in the initial stage of the disease, the survival rate is estimated at 60%-70%, but, for advanced forms, the 5-year survival rate is poor with less than 10%, despite the progress in therapies.…”

“…ccRCC is characterized by high aggressiveness and metastatic potential and it displays a high incidence, affecting predominantly people between 60 and 70 years old and it is diagnosed more frequently in males than in females, being classified as the seventh most common cancer among men 2 . The metastatic form is the most aggressive and is associated with a high mortality rate: approximately 20%–30% of patients have metastases and about 30% of those with an advanced stage ccRCC will develop metastases, mainly in lungs, liver, and bones and, for about 15%, in lymph nodes 3,4 . Among genitourinary cancers, ccRCC displays the highest mortality rate and clinical outcomes are still unsatisfactory mainly due to drug resistance which, coupled with a late diagnosis and a tendency to metastasize, leads to a very low survival.…”